2024
Treatment patterns and clinical outcomes in patients with EGFR-mutated non-small cell lung cancer after progression on osimertinib
Robinson N, Canavan M, Zhan P, Udelsman B, Pathak R, Boffa D, Goldberg S. Treatment patterns and clinical outcomes in patients with EGFR-mutated non-small cell lung cancer after progression on osimertinib. Clinical Lung Cancer 2024 PMID: 39462746, DOI: 10.1016/j.cllc.2024.09.006.Peer-Reviewed Original ResearchNon-small cell lung cancerEGFR-mutant non-small cell lung cancerFirst-line osimertinibContinuation of osimertinibImmune checkpoint inhibitorsTyrosine kinase inhibitorsCell lung cancerRetrospective cohort studyOverall survivalTreatment regimensLung cancerAdvanced epidermal growth factor receptorAssociated with increased PFSAssociated with superior PFSSecond-line treatment regimenEGFR exon 19 deletionRetrospective cohort study of patientsEGFR tyrosine kinase inhibitorsAssociated with prolonged survivalCohort study of patientsSecond-line treatment regimensExon 19 deletionFirst-line therapyEpidermal growth factor receptorFirst-line treatmentSurgical and Endoscopic Management of Clinical T1b Esophageal Cancer
Ayoade O, Canavan M, De Santis W, Zhan P, Boffa D. Surgical and Endoscopic Management of Clinical T1b Esophageal Cancer. Journal Of Thoracic And Cardiovascular Surgery 2024 PMID: 38925509, DOI: 10.1016/j.jtcvs.2024.06.011.Peer-Reviewed Original ResearchEsophageal cancerTumor attributesEsophagectomy patientsEndoscopic treatmentAccelerated time failure modelsEndoscopic managementTumor size > 1 cmFactors associated with upstagingOccult lymph node metastasisAssociated with improved survivalAssociated with lymphovascular invasionEffect of esophagectomyT1b esophageal cancerTreatment naive patientsNational Cancer DatabaseWell-differentiated tumorsKaplan Meier analysisLymph node metastasisPoor tumor differentiationTime failure modelsNodal upstagingLymphovascular invasionOverall survivalEndoscopic patientsMeier analysisSalvage lung resection after immunotherapy is feasible and safe
Nemeth A, Canavan M, Zhan P, Udelsman B, Ely S, Wigle D, Martin L, Yang C, Boffa D, Dhanasopon A. Salvage lung resection after immunotherapy is feasible and safe. JTCVS Open 2024, 20: 141-150. PMID: 39296459, PMCID: PMC11405986, DOI: 10.1016/j.xjon.2024.03.018.Peer-Reviewed Original ResearchNon-small cell lung cancerComplete pathologic responseSalvage lung resectionNational Cancer DatabaseLength of stayStages I-IVLung resectionOligo-progressionOverall survivalSalvage surgeryComplete resection (R0Comprehensive multidisciplinary treatment planHigher R0 resection rateCohort study of patientsInitiation of immunotherapyR0 resection rateTreated with immunotherapySalvage treatment optionMortality rateCell lung cancerLow patient morbidityMedian length of stayKaplan-Meier analysisMultidisciplinary treatment planStudy of patients
2023
Association of Wildfire Exposure While Recovering From Lung Cancer Surgery With Overall Survival
Zhang D, Xi Y, Boffa D, Liu Y, Nogueira L. Association of Wildfire Exposure While Recovering From Lung Cancer Surgery With Overall Survival. JAMA Oncology 2023, 9: 1214-1220. PMID: 37498574, PMCID: PMC10375383, DOI: 10.1001/jamaoncol.2023.2144.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerOverall survivalWorse overall survivalLung cancerNSCLC surgeryCohort studyHazard ratioSurgical resectionNSCLC resectionLong-term overall survivalNational Cancer DatabaseLung cancer surgeryLymph node involvementCell lung cancerHealth insurance typeHealth hazardsHospital dischargeNode involvementCancer surgeryStudy endTumor sizeCancer DatabaseInsurance typeHigh riskUnexposed individualsOverall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery
Udelsman B, Canavan M, Zhan P, Ely S, Park H, Boffa D, Mase V. Overall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery. Journal Of Thoracic And Cardiovascular Surgery 2023, 167: 822-833.e7. PMID: 37500052, DOI: 10.1016/j.jtcvs.2023.07.021.Peer-Reviewed Original ResearchNon-small cell lung cancerStereotactic body radiotherapyStage I non-small cell lung cancerLow-comorbidity patientsCell lung cancerOverall survivalSurgical managementLung cancerSurgical resectionBody radiotherapyClinical stage I non-small cell lung cancerEarly-stage non-small cell lung cancerPropensity score-matched cohortPropensity score-matched patientsPropensity score-matched analysisEarly-stage lung cancerLong-term OSNational Cancer DatabaseProportion of patientsCancer DatabasePatientsSBRT patientsSurgeryCancerMortality
2021
Randomized Phase II Study of PET Response–Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial
Goodman KA, Ou FS, Hall NC, Bekaii-Saab T, Fruth B, Twohy E, Meyers MO, Boffa DJ, Mitchell K, Frankel WL, Niedzwiecki D, Noonan A, Janjigian YY, Thurmes PJ, Venook AP, Meyerhardt JA, O'Reilly EM, Ilson DH. Randomized Phase II Study of PET Response–Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. Journal Of Clinical Oncology 2021, 39: 2803-2815. PMID: 34077237, PMCID: PMC8407649, DOI: 10.1200/jco.20.03611.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinChemoradiotherapyCombined Modality TherapyEsophageal NeoplasmsFemaleFluorodeoxyglucose F18FluorouracilFollow-Up StudiesHumansLeucovorinMaleMiddle AgedOxaliplatinPositron-Emission TomographyPrognosisRadiopharmaceuticalsSurvival RateYoung AdultConceptsPositron emission tomographyRepeat positron emission tomographyPET respondersEsophagogastric junction adenocarcinomaStandardized uptake valueInduction FOLFOXPET nonrespondersPCR rateOverall survivalJunction adenocarcinomaPathologic complete response rateRandomized phase II studyBaseline positron emission tomographyMaximum standardized uptake valueInduction chemotherapy regimenComplete response rateEarly response assessmentMedian overall survivalPhase II studyPrimary end pointCombined modality therapySame chemotherapyChemotherapy regimenEligible patientsII studyOutcomes of surgically managed primary lung sarcomas: a National Cancer Database analysis
Li AX, Resio BJ, Canavan ME, Papageorge M, Boffa DJ, Blasberg JD. Outcomes of surgically managed primary lung sarcomas: a National Cancer Database analysis. Journal Of Thoracic Disease 2021, 0: 0-0. PMID: 34277037, PMCID: PMC8264694, DOI: 10.21037/jtd-21-1.Peer-Reviewed Original ResearchPrimary lung sarcomaNational Cancer DatabaseLung sarcomaOverall survivalSurgical resectionMultivariable Cox proportional hazards modelsNon-small cell lung cancer patientsNational Cancer Database AnalysisCell lung cancer patientsCox proportional hazards modelCharlson-Deyo scoreFive-year OSMultivariable Cox modelPositive lymph nodesMajority of patientsLung cancer patientsHigh tumor gradeHigh-grade tumorsDifferent histologic subtypesProportional hazards modelAdjuvant chemotherapyParenchymal resectionPulmonary malignancyWorse survivalAdjusted mortalityAdjuvant Chemotherapy for T4 Non-Small Cell Lung Cancer with Additional Ipsilateral Lung Nodules
Li AX, Flores K, Canavan ME, Boffa DJ, Blasberg JD. Adjuvant Chemotherapy for T4 Non-Small Cell Lung Cancer with Additional Ipsilateral Lung Nodules. The Annals Of Thoracic Surgery 2021, 113: 421-428. PMID: 33684345, DOI: 10.1016/j.athoracsur.2021.02.042.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerDifferent ipsilateral lobeCell lung cancerAdditional tumor nodulesT4 non-small cell lung cancerAdjuvant chemotherapyIpsilateral lobeT4 diseaseTumor nodulesLung cancerT4 tumorsOverall survivalSurgical resectionIIIA non-small cell lung cancerAdjuvant multiagent chemotherapyResectable stage IINational Cancer DatabaseFurther prospective studiesLymph node metastasisMultiagent chemotherapyNode metastasisPrimary outcomeProspective studyPatient populationCancer DatabaseChemoradiation as a nonsurgical treatment option for early-stage esophageal cancers: a retrospective cohort study
Pathak R, Canavan ME, Walters S, Salazar MC, Boffa DJ. Chemoradiation as a nonsurgical treatment option for early-stage esophageal cancers: a retrospective cohort study. Journal Of Thoracic Disease 2021, 13: 140-148. PMID: 33569194, PMCID: PMC7867841, DOI: 10.21037/jtd-20-1187.Peer-Reviewed Original ResearchEarly-stage esophageal cancerEsophageal cancerOverall survivalDefinitive non-surgical treatmentComorbidity-free patientsCT1/T2National Cancer DatabaseRetrospective cohort studyNon-surgical treatmentSubset of patientsGoals of careKaplan-Meier curvesNonsurgical treatment optionsKaplan-Meier estimatesInoperable patientsCohort studyNonsurgical approachCure rateTreatment optionsCancer patientsEndoscopic excisionCancer DatabaseTumor removalChemoradiationPatients
2019
Digital Inference of Immune Microenvironment Reveals Low-Risk Subtype of Early Lung Adenocarcinoma
Kurbatov V, Balayev A, Saffarzadeh A, Heller DR, Boffa DJ, Blasberg JD, Lu J, Khan SA. Digital Inference of Immune Microenvironment Reveals Low-Risk Subtype of Early Lung Adenocarcinoma. The Annals Of Thoracic Surgery 2019, 109: 343-349. PMID: 31568747, DOI: 10.1016/j.athoracsur.2019.08.050.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma of LungAdultAgedCohort StudiesDatabases, FactualDisease-Free SurvivalFemaleHumansImmunotherapyKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPneumonectomyPrognosisProportional Hazards ModelsRetrospective StudiesRisk AssessmentSurvival AnalysisTumor MicroenvironmentConceptsTumor immune microenvironmentImmune microenvironmentLung adenocarcinomaOverall survivalRisk groupsMast cellsCox proportional hazard modelingEarly-stage lung adenocarcinomaLow-risk subtypesKaplan-Meier analysisPathological staging systemProportional hazard modelingImproved clinical outcomesCancer immune microenvironmentImmune cell typesEarly lung adenocarcinomaActivation stateClinical outcomesValidation cohortMacrophage contentStaging systemMultivariable modelCIBERSORT analysisPatientsClinical decisionComparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer
Uhlig J, Case MD, Blasberg JD, Boffa DJ, Chiang A, Gettinger SN, Kim HS. Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer. JAMA Network Open 2019, 2: e199702. PMID: 31433481, PMCID: PMC6707019, DOI: 10.1001/jamanetworkopen.2019.9702.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAdolescentAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantComparative Effectiveness ResearchDatabases, FactualFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPneumonectomyProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSurvival RateTreatment OutcomeYoung AdultConceptsStage IV non-small cell lung cancerNon-small cell lung cancerPrimary tumor siteSuperior overall survivalSystemic therapySurgical resectionCell lung cancerExternal beam radiotherapyOverall survivalSurvival benefitLocal treatmentTumor siteTumor characteristicsLung cancerTreatment groupsMultivariable Cox proportional hazards regression modelsOligometastatic non-small cell lung cancerStage IV squamous cell carcinomaSurvival rateCox proportional hazards regression modelProportional hazards regression modelsComparative effectiveness research studyCancer-specific factorsNational Cancer DatabaseStage IV diseaseBenefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database.
Dendy Case M, Uhlig J, Blasberg J, Boffa D, Chiang A, Gettinger S, Kim H. Benefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database. Journal Of Clinical Oncology 2019, 37: 8545-8545. DOI: 10.1200/jco.2019.37.15_suppl.8545.Peer-Reviewed Original ResearchNon-small cell lung cancerNational Cancer DatabaseStage IV non-small cell lung cancerStage IV NSCLC patientsSystemic therapyOverall survivalSurgical resectionPatient demographicsNSCLC patientsCancer DatabaseMultivariable Cox proportional hazards modelsSquamous cell carcinoma patientsPropensity scoreMultivariable logistic regression modelCox proportional hazards modelSuperior overall survivalCell carcinoma patientsCell lung cancerLung cancer treatmentProportional hazards modelLogistic regression modelsLimited nodalTA patientsMetastatic diseaseMultivariable adjustment
2018
Variable impact of prior cancer history on the survival of lung cancer patients
Monsalve AF, Hoag JR, Resio BJ, Chiu AS, Brown LB, Detterbeck FC, Blasberg JD, Boffa DJ. Variable impact of prior cancer history on the survival of lung cancer patients. Lung Cancer 2018, 127: 130-137. PMID: 30642541, DOI: 10.1016/j.lungcan.2018.11.040.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPrior cancer historyNational Cancer DatabaseCancer historyOverall survivalNSCLC patientsMultivariable Cox proportional hazards regression modelsTreatment approachesCox proportional hazards regression modelProportional hazards regression modelsKaplan-Meier survival curvesNSCLC patient survivalCell lung cancerHazards regression modelsLung cancer patientsPrior cancerPrior malignancyNSCLC survivalPatient survivalCancer patientsLung cancerCancer DatabasePatient's potentialPrior historyPatients
2017
Effectiveness of local therapy for stage I non–small-cell lung cancer in nonagenarians
Arnold BN, Thomas DC, Rosen JE, Salazar MC, Detterbeck FC, Blasberg JD, Boffa DJ, Kim AW. Effectiveness of local therapy for stage I non–small-cell lung cancer in nonagenarians. Surgery 2017, 162: 640-651. PMID: 28697883, DOI: 10.1016/j.surg.2017.04.025.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overCarcinoma, Non-Small-Cell LungConfidence IntervalsDatabases, FactualDisease-Free SurvivalFemaleGeriatric AssessmentHumansKaplan-Meier EstimateLogistic ModelsLung NeoplasmsMaleMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingOdds RatioPneumonectomyProportional Hazards ModelsRadiotherapyRegistriesRisk AssessmentSecondary PreventionSurvival AnalysisConceptsCell lung cancerLocal therapyLung cancerStage IRelative survivalStereotactic body radiation therapyNational Cancer DatabaseBetter overall survivalBody radiation therapyOlder patientsOverall survivalPatient ageYounger patientsOverall mortalityPrimary outcomeCancer DatabaseTreatment outcomesTreatment decisionsRadiation therapyPatientsTherapyCancerNonagenariansTreatmentSurvival
2016
Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall
Gao SJ, Corso CD, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall. Clinical Lung Cancer 2016, 18: 169-177.e4. PMID: 27890561, DOI: 10.1016/j.cllc.2016.08.005.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdjuvant chemotherapyAdjuvant chemoradiation therapyUnderwent surgeryChemoradiation therapyChest wall resectionRadiation therapyMargin statusTumor sizeLung cancerWall resectionNode-negative lung cancerNational Cancer Data BaseCox proportional hazards modelMargin-positive patientsChest wall invasionCell lung cancerLog-rank testStage IIB tumorsProportional hazards modelAdjuvant therapyAdjuvant treatmentOverall survivalMultivariable analysisIIB tumors75P PD-L1 expression on circulating CD45(-) cells is an independent prognostic factor for overall survival (OS) in patients (Pts) across all stages of treatment-naïve lung cancer in a prospective, multicenter study
Graf R, Lu D, Krupa R, Louw J, Dugan L, Jendrisak A, Orr S, Bethel K, Wang Y, Suraneni M, Landers M, Boffa D, Nieva J, Bazhenova L, Salazar M, Makani S, Magana M, Dittamore R. 75P PD-L1 expression on circulating CD45(-) cells is an independent prognostic factor for overall survival (OS) in patients (Pts) across all stages of treatment-naïve lung cancer in a prospective, multicenter study. Annals Of Oncology 2016, 27: vi22. DOI: 10.1093/annonc/mdw363.23.Peer-Reviewed Original ResearchProgrammed cell death-1 ligand (PD-L1) expression on circulating CD45(-) cells is an independent prognostic factor for overall survival in patients (Pts) with lung cancer in a prospective, multicenter cohort.
Boffa D, Nieva J, Bazhenova L, Krupa R, Lu D, Graf R, Louw J, Dugan L, Jendrisak A, Salazar M, Makani S, Magana M, Orr S, Bethel K, Wang Y, Marrinucci D, Dittamore R. Programmed cell death-1 ligand (PD-L1) expression on circulating CD45(-) cells is an independent prognostic factor for overall survival in patients (Pts) with lung cancer in a prospective, multicenter cohort. Journal Of Clinical Oncology 2016, 34: 8524-8524. DOI: 10.1200/jco.2016.34.15_suppl.8524.Peer-Reviewed Original Research